Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

BrainCells Issued First Patent for Neurogenic Drug Combinations

By Drug Discovery Trends Editor | May 3, 2010

BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary neural stem cell platform technology to identify novel compounds for the treatment of central nervous system (CNS) diseases, announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,678,808 entitled, “5 HT Receptor Mediated Neurogenesis.” The patent gives BrainCells coverage for treating depression with buspirone, a 5HTR agent, in combination with melatonin, by way of stimulating the formation of new nerve cells, or neurogenesis. Buspirone and melatonin are the two active agents in BCI-952, a compound that was selected by BrainCells’ platform and that demonstrated proof-of-concept in a clinical study.

“This patent marks an important step in our development of BCI-952 for Major Depressive Disorder,” said Jim Schoeneck, CEO at BrainCells. “It covers the combination of a 5HTR compound with another agent at any synergistic level, giving our scientists the flexibility to develop BCI-952 at an optimum dose. Once the oral formulation of the buspirone-melatonin combination is complete, we plan to initiate clinical studies to confirm the effectiveness of BCI-952.”

Results from the six week proof-of-concept clinical study of BCI-952 showed that it had a positive clinical impact on depression symptoms with improvements in multiple clinical endpoints of depression including the Clinical Global Impressions Scale for improvement (CGI-I), the Inventory of Depressive Symptoms (IDSC30), the Hamilton Anxiety Scale and the patient-rated Quick Inventory of Depressive Symptomatology (QIDS SR-16) as compared to placebo or buspirone alone. BCI-952 was also well tolerated, with a safety profile similar to placebo.

Date: May 3, 2010
Source: BrainCells Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50